HutchMed Ltd Initiates Phase I Clinical Study for SHP2 Inhibitor HMPL-415 in Solid Tumors
China-based HutchMed Ltd (NASDAQ: HCM; HKG: 0013) has announced the initiation of a Phase I...
GenScript Biotech Expands cGMP Manufacturing for Gene and Cell Therapy in Zhenjiang Facility
China-based GenScript Biotech Corporation (HKG: 1548) has announced the expansion of its current Good Manufacturing...
China’s NAFR Enhances Tax Benefits for Private Health Insurance Purchases
The National Administration of Financial Regulation (NAFR) in China has issued a Notification indicating that...
Jacobio Pharma Secures RMB 150 Million Investment to Advance Pipeline Programs
China-based Jacobio Pharma (HKG: 1167) has announced receiving RMB 150 million (USD 20.7 million) in...
Genesis MedTech Secures Chinese Market Approval for ArtiSential Laparoscopic Surgical Device
Singapore-based Genesis MedTech has announced that it has received market approval in China for its...
Shanghai Fosun Pharmaceutical Submits Daxibotulinumtoxin A (RT002) for NMPA Approval
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a China-based pharmaceutical company, has announced a...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-1703 Clinical Study
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a China-based pharmaceutical company, has announced receiving approval...
C-Mer Eye Care Holdings Ltd Partners with Hong Kong Ophthalmologist for Novel Drug Development
China-based C-Mer Eye Care Holdings Ltd (HKG: 3309) has announced the establishment of a joint...
ChengDu ShengNuo Biotechnology Aims to Raise RMB 160 Million for Peptide Drug CDMO Expansion
China-based ChengDu Shengnuo Biotechnology Co., Ltd., (SHA: 688117) has announced plans to raise up to...
Peijia Medical Receives NMPA Approval for DCwire Micro Guide Wire Device in China
Peijia Medical Ltd (HKG: 9996), a leading Chinese firm in the neurointerventional field, has announced...
Chime Biologics, Leads Biolabs, and BeiGene Form Strategic Partnership for LAG-3 mAb LBL-007
Wuhan-based Contract Development and Manufacturing Organization (CDMO) Chime Biologics has signed a strategic cooperation agreement...
Sirnaomics Ltd Partners with Edirna Inc. to Advance RNA Editing Therapy
Sirnaomics Ltd (HKG: 2257), a leading company in the field of RNA therapeutics, has announced...
CDE Launches Trial Procedures for Adding Pediatric Information to Drug Inserts
The Center for Drug Evaluation (CDE) has released the “Work Procedures for Adding Children’s Drug...
Sino Biopharmaceutical’s F-star Therapeutics Inks Third Licensing Deal with Takeda for Immunotherapies
Sino Biopharmaceutical Ltd (HKG: 1177) has announced a third licensing agreement between its subsidiary, F-star...
3SBio Inc. Receives NMPA Approval for Nalfurafine Tablets to Treat Hemodialysis-Related Pruritus
China-based 3SBio Inc. (HKG: 1530) has announced receiving marketing approval from the National Medical Products...
Tot Biopharmaceutical and GL-Biotech Collaborate on DisacLink Technology for ADC Advancements
China-based Tot Biopharma International Co., Ltd (HKG: 1875) has announced a strategic partnership with compatriot...
Jiangsu Hengrui Pharmaceuticals Gets NMPA Approval for Esflurbiprofen Patch Clinical Study
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...
Biocytogen Pharmaceuticals Enters Antibody License Agreement with Pheon Therapeutics for ADC Development
China-based Biocytogen Pharmaceuticals (Beijing) Co., Ltd (HKG: 2315) has announced an antibody license agreement with...
Nanjing Kati Medical and Leman Biotech Partner to Advance Immune Metabolism Reprogramming in CAR-T Therapy
Nanjing Kati Medical Technology Co., Ltd, a China-based company, has entered into a partnership with...
Brii Biosciences Expands Collaboration with VBI Vaccines on Hepatitis B Virus Therapies
China-based Brii Biosciences Ltd (HKG: 2137) has announced an expanded license agreement with US firm...